Wall Street Trader schreef op 3 maart 2020 10:32:
Galapagos and partner Gilead are going full steam ahead in IPF.US Office Head/1690 Assistant PLWork closely with the PL to ensure effective and productive collaboration with Gilead 1690 Project Team members, grounded in mutual respect and collaboration, and in close collaboration with the Alliance Management and Project Management.
Lead by example with respect to Galapagos way of working and Galapagos culture, and support the team in the changing environment. Promote respectful and inclusive teamwork.careers.glpg.com/o/us-office-head1690...1Q21 decision will be a “go/no go decision” with few other details.
"Investors are very familiar with filgotinib and also '1690 in IPF. But the rest of the pipeline is still not so well understood or appreciated," van de Stolpe said, highlighting a communication challenge that meetings like the JPM conference can help address.
Quote Onno;
"Ik wil dat IPF-medicijn ontwikkeld zien".
The futility analysis will now be conducted once 28% of patients (originally 25%) have completed 52 weeks of treatment. This pushed the projected timing of the futility analysis back from 3Q20 to 1Q21. However, analysis of a larger sample of patients will provide increased confidence in the trial should the futility analysis recommend trial continuation. Expect the trial to be fully or nearly fully enrolled by the time of the futility analysis, setting GLPG1690 on pace for a projected topline readout in 1H22 with
a U.S. market launch projected in 2023 should the drug gain regulatory approval.
GLPG1690 could be disruptive in IPF and a real game changer for Galapagos to grow up into a European biotech powerhouse.